#CutaneousSCC
LightNews LightNews
ascopost.bsky.social
Avelumab + cetuximab showed promising activity in advanced cutaneous SCC in a phase II trial led by Dr. Shailender Bhatia and colleagues. Details on ORR, DOR, and more:
🔗 ascopost.com/news/june-20...
#CutaneousSCC #Immunotherapy
Avelumab Plus Cetuximab in Advanced Cutaneous Squamous Cell Carcinoma
In a phase II trial (Alliance A091802) reported in the Journal of Clinical Oncology, Zandberg et al investigated the survival benefit of adding cetuximab to avelumab in patients with advanced cutaneou...
ascopost.com
June 18, 2025 at 3:07 PM
onclive.bsky.social
🩺 Experts discuss how adjuvant immunotherapy, improved risk stratification, and a multidisciplinary approach are redefining care for patients with cSCC. 📊🧬
Read more ➡️ www.onclive.com/view/adjuvan...
#SkinCancer #CutaneousSCC #cSCC #Immunotherapy #MultidisciplinaryCare #PrecisionOncology #Oncology
Adjuvant Immunotherapy, Risk Stratification, and Multidisciplinary Care Redefine CSCC Management | OncLive
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss evolving evidence-based decision-making across CSCC.
www.onclive.com
July 15, 2026 at 2:21 PM